Skip to main content
Log in

Hepatoblastoma screening of low-birthweight children cost effective in US

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Reference

  • MacDonell-Yilmaz R, et al. Cost-effectiveness Analysis of Screening Extremely Low Birthweight Children for Hepatoblastoma Using Serum Alpha-fetoprotein. Journal of Pediatrics : 26 May 2020. Available from: URL: http://doi.org/10.1016/j.jpeds.2020.05.041

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hepatoblastoma screening of low-birthweight children cost effective in US. PharmacoEcon Outcomes News 855, 17 (2020). https://doi.org/10.1007/s40274-020-6882-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-6882-6

Navigation